IP Library › Granted Patent US 11,617,743
Granted Patent B2
US 11,617,743 · App. 16/330,601 · Granted Apr 4, 2023

Formulations of hydroxypyridonate actinide/lanthanide decorporation agents

Inventors: Rebecca J. Abergel (Kensington, CA); Taylor A. Choi (South San Francisco, CA); Kenneth N. Raymond (Berkeley, CA); David K. Shuh (Oakland, CA)
Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A61K31/444A61K9/0019A61K9/0056A61K9/0095A61K9/1611A61K9/1623A61K9/1652A61K9/2009A61K9/2018A61K9/2054A61P39/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,617,743
App. No.
16/330,601
Granted
Apr 4, 2023
Kind
B2
Abstract

Provided herein are pharmaceutical formularions comprising a 1,2-HOPO chelating agent and/or 3,2-HOPO chelating agent.

Claims (21)

1. A pharmaceutical composition comprising:

a 1,2-HOPO chelating agent in an amount from about 100 to about 1500 mg; and

sodium oleate,

wherein the 1,2-HOPO chelating agent is 3,4,3-L1-1,2-HOPO.

2. The pharmaceutical composition of claim 1 , wherein sodium oleate is present at about 70 to about 130 mg.

3. The pharmaceutical composition of claim 1 , wherein sodium oleate is present at 8 to 12% of a total weight of the composition.

4. The pharmaceutical composition of claim 3 , wherein sodium oleate is about 11% of a total weight of the composition.

5. The pharmaceutical composition of claim 3 , wherein the 3,4,3-L1-1,2-HOPO chelating agent is present in an amount from 300 to 1500 mg.

6. The pharmaceutical composition of claim 4 , wherein the 3,4,3-L1-1,2-HOPO chelating agent is present in an amount from 400 to 1200 mg.

7. The pharmaceutical composition of claim 4 , wherein the 3,4,3-L1-1,2-HOPO chelating agent is present in an amount from 100 to 300 mg.

8. The pharmaceutical composition of claim 4 , wherein the 3,4,3-L1-1,2-HOPO chelating agent is present in an amount of 600 mg.

9. The pharmaceutical composition of claim 1 , wherein the 3,4,3-L1-1,2-HOPO chelating agent is present in an amount from 300 to 1500 mg.

10. The pharmaceutical composition of claim 1 , wherein the 3,4,3-L1-1,2-HOPO chelating agent is present in an amount from 400 to 1200 mg.

11. The pharmaceutical composition of claim 1 , wherein the 3,4,3-L1-1,2-HOPO chelating agent is present in an amount from 100 to 300 mg.

12. The pharmaceutical composition of claim 1 , wherein the 3,4,3-L1-1,2-HOPO chelating agent is present in an amount of 600 mg.

13. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is packaged as a tablet.

14. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is within a capsule.

15. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is within one or more granules.

16. The pharmaceutical composition of claim 7 , wherein the pharmaceutical composition is packaged as a tablet.

17. The pharmaceutical composition of claim 7 , wherein the pharmaceutical composition is within a capsule.

18. The pharmaceutical composition of claim 7 , wherein the pharmaceutical composition is within one or more granules.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 18, 2022
From: UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB
To: UNITED STATES DEPARTMENT OF ENERGY
Reel/Frame 058676/0404 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2019
From: ABERGEL, REBECCA J.; CHOI, TAYLOR A.; RAYMOND, KENNETH N.; SHUH, DAVID K.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 049579/0822 →
Continuity (1)
Related Publication 20210283115A1 · Sep 16, 2021